

LIDDS signs a deal with Alira Health on sell-side support in Licensing

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that, effective immediately, the company will be supported sell-side by Alira health in its Business Development efforts, encompassing licensing of its drug candidates as well as its technology.

Alira Health will collaborate with LIDDS and provide support through its M&A expertise integrated with indepth market, medical, and science understanding to solicit potential licensees, support in the selection of offers, and in negotiations. The collaboration will mark a new era of structured and professionalised business development in LIDDS; and finalising a licensing deal on Liproca Depot has the highest priority in 2023.

Alira Health is a global advisory and clinical research firm with a team comprised of over 600 scientists, strategists, economists, clinicians, and biostatisticians. Alira Health works to fully understand every aspect of their clients' business and offer value at every stage of their corporate and product evolution. One of its service branches features sell-side business development and M&A support, and it is in the capacity that it will serve LIDDS in 2023.

"I have worked with Alira Health in the past and I have been impressed with the clear structure of their work as well as with the results that they have achieved" says Anders Månsson, CEO of LIDDS. "LIDDS needs a professional and structured Business Development process, and we are not enough people to rely only on in-house resources. I am sure the extension of our team through this collaboration with Alira Health, will speed our licensing results and improve our chances of successful dealmaking", he continues.

For additional information, please contact


Anders Månsson, CEO Phone: +46 (0)70 860 47 38

E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO Phone: +46 (0)70 855 38 05

E-mail: jenni.bjornulfson@liddspharma.com

LIDDS' Certified Adviser is Redeye AB





09 January 2023 10:30:00 CET

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Alira Health in brief:

Alira Health is a global advisory and clinical research firm whose mission is to humanise healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle. Learn more: www.alirahealth.com

Attachments

LIDDS signs a deal with Alira Health on sell-side support in Licensing